Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

121. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. (Abstract)

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heart failure decompensation. We aimed to investigate the efficacy of our remote patient management intervention (...) on mortality and morbidity in a well defined heart failure population.The Telemedical Interventional Management in Heart Failure II (TIM-HF2) trial was a prospective, randomised, controlled, parallel-group, unmasked (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. The trial was done in Germany, and patients were recruited from hospitals and cardiology practices. Eligible patients had heart failure, were in New York Heart Association class II or III

2018 Lancet Controlled trial quality: predicted high

122. Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial Full Text available with Trip Pro

Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial Readmissions for heart failure (HF) are a major burden. We aimed to assess whether the extent of improvement in pulmonary fluid content (ΔPC) during HF hospitalization evaluated by lung impedance (LI), or indirectly by other clinical and laboratory parameters, predicts readmissions.The present study is based on pre-defined secondary analysis of the IMPEDANCE-HF extended trial (...) with ΔPC ≤ median for all parameters evaluated in both study groups with the most pronounced difference predicted by LI (P < 0.01). Net reclassification improvement analysis showed that adding LI to the traditional clinical and laboratory parameters improved the predictive power significantly.The extent of ΔPC improvement, primarily the LI based, during HF-hospitalization, and study group allocation strongly predicted readmission and event-free survival time.© 2018 The Authors. ESC Heart Failure

2018 ESC heart failure

123. Iron deficiency in chronic heart failure: case‐based practical guidance Full Text available with Trip Pro

Iron deficiency in chronic heart failure: case‐based practical guidance In patients with chronic heart failure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure recognize iron deficiency as a co-morbidity in chronic heart failure and recommend iron status screening in all (...) newly diagnosed patients with chronic heart failure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented

2018 ESC heart failure

124. Heart failure

, fluid retention, and fatigue; and signs including basal crepitations, and peripheral oedema. Heart failure is (...) classified into two main categories with either a reduced or preserved ejection fraction. Symptoms are classified according to severity using the New York Heart Association (NYHA) functional classification. The most common underlying cause is coronary artery disease. Complications include arrhythmias, depression, cachexia, chronic kidney disease, sexual dysfunction, and sudden cardiac (...) Factors for HF ( Hypertension , Diabetes Mellitus, Metabolic Syndrome, and Atherosclerotic Disease) e249 5. Cardiac Structural Abnormalities 2013 8. Evaluation and Management of Right-Sided Heart Failure : A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided Heart Failure : A Scientific Statement From the American Heart Association | Circulation Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement

2018 Trip Latest and Greatest

125. Sex differences in outcomes of heart failure in an ambulatory, population-based cohort from 2009 to 2013 Full Text available with Trip Pro

Sex differences in outcomes of heart failure in an ambulatory, population-based cohort from 2009 to 2013 Heart failure remains a substantial cause of morbidity and mortality in women. We examined the sex differences in heart failure incidence, mortality and hospital admission in a population-based cohort.All Ontario residents who were diagnosed with heart failure in an ambulatory setting between Apr. 1, 2009, and Mar. 31, 2014, were included in this study. Incident cases of heart failure were (...) captured through physician billing using a validated algorithm. Outcomes were mortality and hospital admission for heart failure within 1 year of the diagnosis. Probability of death and hospital admission were calculated using the Kaplan-Meier method. The hazard of death was assessed using a multivariable Cox proportional hazard model.A total of 90 707 diagnoses of heart failure were made in an ambulatory setting during the study period (47% women). Women were more likely to be older and more frail

2018 EvidenceUpdates

126. Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure Full Text available with Trip Pro

Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure 30416736 2018 12 07 2050-3369 7 3 2018 Aug Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure. 218-219 10.15420/aer.2018.7.3.L1 Theodoros Zografos Z eng Journal Article England Arrhythm Electrophysiol Rev 101637930 2050-3369 2018 11 13 6 0 2018 11 13 6 0 2018 11 13 6 1 ppublish 30416736 10.15420/aer (...) .2018.7.3.L1 PMC6141951 Circulation. 2013 Feb 5;127(5):613-23 23275383 Europace. 2012 Jan;14(1):81-91 21798880 ESC Heart Fail. 2018 Oct;5(5):965-976 29984912 Heart Rhythm. 2018 Mar;15(3):460-468 29107697 Pacing Clin Electrophysiol. 2006 Oct;29(10):1063-8 17038137 Arrhythm Electrophysiol Rev. 2018 Jun;7(2):103-110 29967682 N Engl J Med. 2013 Apr 25;368(17):1585-93 23614585 J Am Coll Cardiol. 1999 Feb;33(2):311-6 9973008 Arrhythm Electrophysiol Rev. 2017 Dec;6(4):159-160 29326829 Eur Heart J. 2015 Apr

2018 Arrhythmia & electrophysiology review

127. Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation Full Text available with Trip Pro

Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation Functional mitral regurgitation is complicating end-stage heart failure and potential heart transplantation by increasing pulmonary artery pressures. The aim of the present study was to investigate feasibility and haemodynamic effects of percutaneous mitral valve edge-to-edge repair using the MitraClip™ device in patients with end-stage heart (...) failure awaiting heart transplantation.In this retrospective study, we identified nine patients suffering from end-stage heart failure listed for heart transplantation in whom moderate-severe or severe functional mitral regurgitation was recognized and treated with percutaneous mitral valve edge-to-edge repair. Twenty-two patients listed for heart transplantation and presenting with moderate-severe or severe functional mitral regurgitation treated in the pre-MitraClip™ era served as controls. Patients

2018 ESC heart failure

128. The effects of a low-carbohydrate diet on oxygen saturation in heart failure patients: a randomized controlled clinical trial. Full Text available with Trip Pro

The effects of a low-carbohydrate diet on oxygen saturation in heart failure patients: a randomized controlled clinical trial. Nutritional therapy in heart failure (HF) patients has been focused on fluid and sodium restriction with the aim of decreasing volume overload. However, these recommendations are not well established and sometimes controversial.To evaluate the effect of the consumption of a low-carbohydrate diet on oxygen saturation, body composition and clinical variables during two (...) months of follow-up in chronic, stable heart failure patients.In a parallel group randomized controlled clinical trial, 88 ambulatory patients were randomly assigned to a low-carbohydrate diet group (40% carbohydrates, 20% protein and 40% fats [12% saturated, 18% monounsaturated and 10% polyunsaturated]) or a standard diet group (50% carbohydrates, 20% protein and 30% fats [10% saturated, 10% monounsaturated and 10% polyunsaturated]) for two months. Diets were normocaloric in both groups. At baseline

2018 Nutricion hospitalaria Controlled trial quality: uncertain

129. Effect of the self-management education program on the quality of life in people with chronic heart failure: a randomized controlled trial Full Text available with Trip Pro

Effect of the self-management education program on the quality of life in people with chronic heart failure: a randomized controlled trial Chronic Heart Failure (CHF) is a syndrome that negatively affects a person's Quality of Life (QOL). The efficient self-management education program increases the individual's abilities and skills for following and participating in a long-term healthcare plan.The aim of this study was to determine the effect of the self-management education program on QOL (...) sessions followed for a 3-month period. The Iranian heart failure QOL questionnaire was used for data collection before and after the intervention. The independent-samples and paired-samples t-tests, Chi-square and Fisher exact tests were used for data analysis via the SPSS v.16 software. P<0.05 was considered statistically significant.No statistically significant differences were reported between the groups in terms of demographic and clinical characteristics, indicating that they were homogeneous

2018 Electronic physician Controlled trial quality: uncertain

130. Sacubitril–valsartan in heart failure and multimorbidity patients Full Text available with Trip Pro

Sacubitril–valsartan in heart failure and multimorbidity patients The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit the functionality of patients. Sacubitril-valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little evidence about the improvement on functionality. The aim of our study is to analyse the improvement of the functional class and the 6 min (...) an improvement in the NYHA functional class.Sacubitril-valsartan relieves symptoms and improves functional class prognostic risk of patients with advanced HFrEF and co-morbidity.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

131. Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues Full Text available with Trip Pro

Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues Pulmonary hypertension (PH) is a common and severe complication of heart failure (HF). Consequently, HF is the leading cause of PH. For many years, specialists have attempted to better understand the pathophysiology of PH in HF, to define its prevalence and its impact on prognosis in order to improve the therapeutic management of these patients. Nowadays, despite the recent guidelines published (...) on the subject, several points remain unclear or debated, and until now, no study has demonstrated the efficacy of any treatment. The aim of this review is to report the evolution of the concepts on post-capillary PH (diagnosis, prevalence, prognosis, and therapeutics). The main issues are raised, focusing especially on the link between structural alterations and haemodynamic abnormalities, to discuss the possible reasons for treatment failures and future potential targets.© 2018 The Authors. ESC Heart

2018 ESC heart failure

132. Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization Full Text available with Trip Pro

Diagnosing and grading heart failure with tomographic perfusion lung scintigraphy: validation with right heart catheterization Pulmonary congestion remains a diagnostic challenge in patients with heart failure (HF). The recommended method, chest X-ray (CXR), lacks in accuracy, whereas quantitative tomographic lung scintigraphy [ventilation/perfusion single-photon emission computed tomography (V/P SPECT)] has shown promising results but needs independent validation. The aim of this study (...) congestion in the clinical setting.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

133. Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment Full Text available with Trip Pro

Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment Left atrium (LA) dilation is associated with adverse cardiovascular (CV) outcomes. Blood stasis, thrombus formation and atrial fibrillation may occur, especially in heart failure (HF) patients. It is not known whether preventive antithrombotic treatment may decrease the incidence of CV events in HF patients with LA enlargement. We investigated the relationship between LA enlargement (...) .© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: uncertain

134. Identifying cut‐off scores for interpretation of the Heart Failure Impact Questionnaire Full Text available with Trip Pro

Identifying cut‐off scores for interpretation of the Heart Failure Impact Questionnaire Heart failure (HF) influences health-related quality of life. However, the factors that contribute to health-related quality of life remain unclear in Taiwan. We aim to identify the factors influencing health-related quality of life in HF patients.Hospitalized HF (N = 225) patients were included from April 2011 to April 2014. Health-related quality of life was assessed by using the 36-Item Short-Form (...) Health Survey (SF-36) and the Minnesota Living with Heart Failure Questionnaire. A new cut-off was conducted based on the combination of SF-36 and Minnesota Living with Heart Failure questionnaire.There were significant differences between good and poor quality groups on age, gender, education levels, occupational classification caregiver, New York Heart Association classes, and the numbers of comorbidities. The logistic regression analysis showed that the number of comorbidities was more than three

2018 Nursing open

135. Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure Full Text available with Trip Pro

-Martin SM Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany. eng Journal Article Comment 2018 07 16 Switzerland Front Cardiovasc Med 101653388 2297-055X Hypertension. 2018 Feb;71(2):280-288 29255073 cardiac hypertrophy exercise heart failure micoRNAs remodeling 2018 06 11 2018 06 28 2018 8 1 6 0 2018 8 1 6 0 2018 8 1 6 1 epublish 30062098 10.3389/fcvm.2018.00095 PMC6054969 J Mol Cell Cardiol. 2007 Jun;42(6):1137-41 17498736 (...) Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure 30062098 2018 11 14 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Commentary: MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure. 95 10.3389/fcvm.2018.00095 Schmitz Boris B Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Muenster, Muenster, Germany. Brand Stefan

2018 Frontiers in cardiovascular medicine

136. Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial Full Text available with Trip Pro

for Heart Failure) trial, we are investigating whether these acute haemodynamic improvements translate into improvements in exercise capacity and heart failure symptoms.This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also (...) Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial In patients with heart failure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute haemodynamic function in this group of patients. In the HOPE-HF (His Optimized Pacing Evaluated

2018 ESC heart failure

137. Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients Full Text available with Trip Pro

Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients Obtain initial estimates of the change in brachial artery endothelial function and maximal oxygen uptake (VO2peak ) with 8 weeks of low-frequency electrical muscle stimulation (LF-EMS) or sham in patients with advanced chronic heart failure.Using a double blind, randomized design, 35 patients with chronic heart failure (New York Heart Association class III-IV) were assigned to 8 weeks (5 × 60 (...) . FMD improved by 2.56% (95% confidence interval: 0.69 to 3.80) with LF-EMS compared with sham (P = 0.07). There were no notable changes in VO2peak .Improvements in FMD with LF-EMS may have a clinically meaningful effect as higher FMD is associated with better prognosis. This is a preliminary finding, and a larger trial is warranted.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: uncertain

138. Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure Full Text available with Trip Pro

studied subjects with HFpEF (n = 28) and HFrEF (n = 25) and without HF (n = 71). Left ventricular (LV) mass and left atrial (LA) volumes were measured with cardiac magnetic resonance imaging. Arginine vasopressin and ANP were measured with enzyme-linked immunosorbent assay. Arginine vasopressin levels were significantly greater in HFpEF [0.96 pg/mL; 95% confidence interval (CI) = 0.83-1.1 pg/mL] compared with subjects without HF (0.69 pg/mL; 95% CI = 0.6-0.77 pg/mL; P = 0.0002). Heart failure (...) Association of arginine vasopressin with low atrial natriuretic peptide levels, left ventricular remodelling, and outcomes in adults with and without heart failure The arginine vasopressin (AVP) pathway has been extensively studied in heart failure (HF) with reduced ejection fraction (HFrEF), but less is known about AVP in HF with preserved EF (HFpEF). Furthermore, the association between AVP and atrial natriuretic peptide (ANP, a well-known inhibitor of AVP secretion) in HF is unknown.We

2018 ESC heart failure

139. Heart failure

Heart failure Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

140. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Full Text available with Trip Pro

Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction. There is uncertainty whether these treatments are beneficial for people with heart failure with preserved ejection fraction and a comprehensive review of the evidence (...) is required.To assess the effects of beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with heart failure with preserved ejection fraction.We searched CENTRAL, MEDLINE, Embase and two clinical trial registries on 25 July 2017 to identify eligible studies. Reference lists from primary studies and review articles were checked for additional studies. There were no language

2018 Cochrane